Valuation: Osteopore Limited

Market Cap 2.08M 1.45M 1.29M 1.21M 1.09M 2.07M 140M 14.49M 5.64M 71.44M 5.45M 5.34M 230M P/E 2024
-0.82x
P/E 2025 -0.33x
Enterprise Value 4.22M 2.95M 2.61M 2.45M 2.22M 4.19M 284M 29.39M 11.43M 145M 11.06M 10.82M 466M EV / Sales 2024
1.71x
EV / Sales 2025 1.28x
Free-Float
83.52%
Yield 2024 *
-
Yield 2025 -
1 day-25.00%
1 week-33.33%
1 month-25.00%
3 months-25.00%
6 months-50.00%
Current year-53.85%
1 week 0
Extreme 0.003
0
1 month 0
Extreme 0.003
0
Current year 0
Extreme 0.003
0.03
1 year 0
Extreme 0.003
0.03
3 years 0
Extreme 0.003
0.84
5 years 0
Extreme 0.003
4.65
10 years 0
Extreme 0.003
22.35
Manager TitleAgeSince
Chief Executive Officer - 2023-07-17
Corporate Secretary - 2024-05-19
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Director/Board Member - 2019-06-23
Director/Board Member - 2024-09-23
Chairman 49 2021-07-31
Change 5-day change 1-year change 3-year change Capi.($)
-25.00%-33.33%-75.00%-99.63% 1.93M
-0.87%-1.64%-25.76%+2.49% 173B
-0.57%+0.69%-10.91%+15.20% 113B
-1.55%+0.67%-23.38%+5.56% 109B
+1.52%+1.45%-46.87%-10.58% 74.44B
-0.31%+2.14%+2.91%+70.88% 60.1B
+3.27%+7.25%+18.14%+67.16% 51.87B
+0.60%-0.21%-5.42%-30.80% 49.21B
-1.22%-2.14%-16.84%+17.05% 41.52B
-2.91%-2.37%+27.47%+1.65% 32.79B
Average -2.68%+0.56%-15.57%+3.90% 70.51B
Weighted average by Cap. -0.32%+0.42%-15.15%+12.70%

Financials

2024 2025
Net sales 2.76M 1.93M 1.71M 1.6M 1.45M 2.74M 186M 19.25M 7.49M 94.86M 7.24M 7.09M 305M 3.06M 2.13M 1.89M 1.77M 1.61M 3.04M 206M 21.3M 8.28M 105M 8.01M 7.84M 337M
Net income -3.35M -2.34M -2.08M -1.94M -1.76M -3.33M -226M -23.35M -9.08M -115M -8.79M -8.6M -370M -3.72M -2.6M -2.31M -2.16M -1.96M -3.7M -251M -25.93M -10.09M -128M -9.76M -9.55M -411M
Net Debt 648K 453K 402K 376K 341K 644K 43.64M 4.52M 1.76M 22.26M 1.7M 1.66M 71.58M 2.14M 1.49M 1.33M 1.24M 1.12M 2.12M 144M 14.9M 5.79M 73.42M 5.6M 5.48M 236M
Projected Income Statement - Annual - Osteopore Limited
Logo Osteopore Limited
Osteopore Limited is a regenerative medicine company engaged in three-dimensional (3D)-printed biomimetic and bioresorbable implants. The Company’s commercialized products are designed to enable natural bone healing across multiple therapeutic areas. The Company’s patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. Through its proprietary manufacturing process, which uses a naturally dissolving polymer, its patented scaffolds enable bone tissue growth, significantly reducing the post-surgery complications commonly associated with permanent bone implants. The Company’s surgical specialty includes craniotomy, orbital floor reconstruction, socket preservation, cranioplasty patient-specific implants (PSI), craniosynostosis, guided bone regeneration, endoscopic transsphenoidal skull base surgery, burr hole restoration with the shunt drainage system, mandible PSI, and immediate implant loading, among others.
Employees
-
Date Price Change Volume
26-10-06 A$0.003000 -25.00% 501,334
26-10-02 A$0.004000 +33.33% 837,531
26-09-30 A$0.003000 -33.33% 1,675,892